Bravo or bravado? Teva, Active move baseline to make PhIII oral MS miss a hit
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and Active Biotech both saw their share price drop sharply after they said that oral laquinimod missed the primary endpoint of a major study, BRAVO – the second pivotal Phase III trial testing the investigational immunomodulator in relapsing-remitting multiple sclerosis. The drug did not significantly reduce annualised relapse rate from baseline to two years over placebo, and yet Teva said an adjusted analysis shows the drug was successful in reducing relapse and that it still plans to submit regulatory applications in the US and EU in early 2012.
You may also be interested in...
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Money talks: Verastem leverages IPO to build cancer stem cell pipeline
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.